Crohn's Disease Therapeutics Market is expected to reach US$ 13.33 billion by 2031

Anti-Inflammatory Biologics Held Largest Crohn’s Disease Therapeutics Market Share in 2023

According to our new research study on "Crohn’s Disease Therapeutics Market Forecast to 2031 – Global Analysis – by Drug Class, Distribution Channel, and Geography," the market is expected to grow from US$ 9.68 billion in 2023 to US$ 13.33 billion by 2031; it is anticipated to record a CAGR of 4.1% from 2023 to 2031. The report emphasizes the trends prevalent in the global market and drivers and deterrents affecting its growth. The increasing prevalence of irritable bowel syndrome, and the rising number of drug developments and regulatory approvals propel the Crohn’s disease therapeutics market growth. However, the high cost associated with Crohn’s disease treatment hampers the market growth. Technological advancements in medical devices for treatments are expected to bring Crohn’s disease therapeutics market trends in the coming years.

Penetration of Precision Medicine for the Treatment of Crohn’s disease will Create an Opportunity for Crohn’s disease therapeutics market growth.

Precision medicine aims to modify the medical therapy to the individual characteristics of each patient, including environmental factors, genetic makeup, lifestyle, and other variables. In Crohn’s disease therapy, precision medicine holds significant assurance for improving the patient's results and minimizing the adverse effects. There are a few ways precision medicine is applied during Crohn’s disease therapy, like genetic profiling, biomarker identification, pharmacogenomics, targeted therapies, and predictive modeling & machine learning. In genetic profiling, genetic sequencing technologies allow the researcher to discover specific genetic variations associated with Crohn’s disease susceptibility and treatment response. This will help them choose the medicine that is likely to respond well and allow for a personalized medication plan.

Crohn’s Disease Therapeutics Market, by Region, 2023(%)

Source: The Insight Partners Analysis

Analyzing and examining the specific biomarkers associated with Crohn’s disease activity will help researchers better access disease severity and predict better outcomes. Targeted therapy is another method in precision medicine that selectively inhibits specific molecules responsible for the inflammatory process responsible for Crohn’s disease. Such personalized treatment enhanced efficiency and reduced systemic toxicity compared with conventional therapies.

Precision medicine further allowed the stratification method, which allowed the stratification of patients into distinct subgroups based on the prior diseases' characteristics, biomarkers, and various genetic signatures. Such treatment approaches can optimize the treatment response rate, minimize the treatment response rate, and improve long-term outcomes in the treatment of Crohn’s disease treatment. 

Predictive modeling and machine learning techniques can analyze complex data sets to identify patterns and predict disease progression. This allows the integration of genetic, clinical, and other relevant data. Predictive modeling techniques can support the clinician in making informed treatment decisions and personalizing the therapy based on patient characteristics.

Precision therapy holds huge potential for the treatment of Crohn’s disease therapy by allowing individualized treatment approaches with diverse genetics, molecular factors, and contributing clinical factors. This treatment plays a prominent role in irritable bowel syndrome and optimizes patient outcomes in managing Crohn’s disease.

Precision medicine has significantly progressed in treating Crohn’s diseases, but many objectives are still unmet on the ground level. It requires a huge data bank, various algorithm tools like big data, Hadoop, and advanced infrastructure with which it can be implemented effectively. Implementing advanced analytics in precision medicine will create huge opportunities for treating Crohn’s disease therapeutics market.

The Crohn’s disease therapeutics market is segmented based on product type, distribution channel, and geography. In terms of drug class type, the market is segmented into Anti-inflammatory Drugs, Immune System Suppressors, Antibiotics, Biologics, Anti-diarrheal, and Pain Reliever. In 2023, the biologics segment held the largest Crohn’s disease therapeutics market share. The anti-inflammatory drugs expected to record the highest CAGR during 2023–2031.

Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy. The hospital pharmacy segment held the largest share of the Crohn’s disease therapeutics market in 2023, and it is further projected to record the highest CAGR during 2023–2031. Hospital pharmacies are associated with hospitals, which are known to provide healthcare services such as disease screening, diagnosis, and treatment with the use of modernized equipment. Thus, the increasing number of admissions in hospitals is likely to drive the sales of Crohn’s disease therapeutics in hospital pharmacies.

Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim Gmbh are among the prominent players profiled in the Crohn’s disease therapeutics market report. In addition, several other players have been studied and analyzed during the study to get a holistic view of the market and its ecosystem. These companies focus on geographic expansions and new product launches to meet the growing demand from consumers worldwide and increase their product range in specialty portfolios. These initiatives by the companies are expected to bolster the Crohn’s disease therapeutics market size during the forecast period.

The Crohn’s disease therapeutics market analysis has been carried out by considering the following segments: product type, distribution channel, and geography. The Crohn’s disease therapeutics market, by drug class type, is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, TNF inhibitors, aminosalicyclates, immunomodulators, and others. Based on distribution channel, the market is further divided into hospitals, specialty clinics, home care, and others. The geographic scope of the Crohn’s disease therapeutics market report encompasses North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com